Halozyme Therapeutics Inc. (NASDAQ:HALO) has announced that its partner, Roche presented data of Part 1 of phase 1b IMscin001 study in a poster at the 2020 virtual ESMO Congress. The study evaluated atezolizumab for subcutaneous administration using the company’s ENHANZE® tech in patients with metastatic or locally advanced non-small cell lung cancer (NSCLC).
Halozyme’s partner presents Phase 1b dose-finding study results
This was a dose-finding study that enrolled 67 advanced/metastatic NSCLC patients that have been treated with chemo in 3 cohorts. According to the presentation, atezolizumab using ENHANZE was well tolerated and offered similar exposure like IV atezolizumab. The results support the advancement in subcutaneous atezlizumab in IMscin001 Part 2, a confirmatory phase III study. Dr. Helen Torley, the CEO, and president of the company said that they are pleased that Roche’s evaluation of atezolizumab with ENHANZE® support development in the Phase III study.
The company is developing the subcutaneous formulation of atezolizumab for faster administration through a subcutaneous injection under the skin. This is compared with the original IV formulation, and thus, it will significantly reduce the time a patient spends in receiving treatment.
ENHANZE® technology enabling faster delivery of drugs
Halozyme’s ENHANZE® technology can significantly reduce the long hours of treatment for NSCLC to just minutes. The tech is a commercially validated solution that has positively helped over 400,00 live of patients through five commercialized across over 10 markets globally. Currently, Halozyme and its collaborators are advancing several therapeutic programs that will bring innovative therapies with the potential of improving the lives of patients globally. The company’s novel enzyme rHuPH20 is what forms the basis of its proprietary ENHANZE® tech, and it is employed in facilitating the delivery of fluids and injected drugs, which thus reduces the treatment burden of drugs.
The company has licensed its ENHANZE® tech to biotech and pharmaceutical companies such as Pfizer, AbbVie, Janssen, Roche, Alexion, Baxalta, and Bristol-Myers Squibb. It drives revenues from these partnerships in royalties and milestone payments in developing and commercializing their products.
